FuelCell Energy Inc vs Zimmer Biomet Holdings Inc — how do they compare? FuelCell Energy Inc trades at $19.42 (market cap $1.59B), while Zimmer Biomet Holdings Inc trades at $97.03 (market cap $18.65B). The key difference: Zimmer Biomet Holdings Inc is far larger — about 11.7× FuelCell Energy Inc's market cap, and Zimmer Biomet Holdings Inc pays a 0.98% dividend while FuelCell Energy Inc pays none. Which is the better fit depends on your goals.
| FCEL | ZBH | |
|---|---|---|
Market Cap | $1.59B | $18.65B |
Sector | Industrials | Health |
52-Week High | $36.01 | $107.71 |
52-Week Low | $3.92 | $79.58 |
Enterprise Value | $1.43B | $25.72B |
Dividend Yield | — | 0.98% |
Signals from Pluang's Aura AI — not financial advice
FCEL trades at $20.43, up 0.54% today, near the analyst consensus target of $20.75. The stock shows a bearish technical signal with negative moving averages, while fundamentals reveal persistent losses: revenue grew to $158.16M in 2025 but net income margin was -132.41%. Recent news highlights partnerships with Siemens and AI data center demand as growth catalysts, though cash flow from operations remains negative at -$125.29M.
FCEL presents high-risk growth potential driven by alternative energy tailwinds and strategic alliances, but investment is speculative due to unprofitability, cash burn, and competitive pressures. Analysts are split evenly between Buy and Hold ratings, reflecting cautious optimism amid financial challenges. The stock's outlook hinges on execution toward profitability and scaling commercial projects.
Zimmer Biomet (ZBH) trades at $96.55, down 0.66% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $103.56. The company reported strong Q2 2026 earnings, beating estimates with EPS of $2.07, and raised its full-year outlook. Revenue growth remains steady, supported by hips, specialty businesses, and technology, though net income margin has moderated from 2023 peaks. Recent corporate news includes a dividend declaration and expansion of its technology center in India.
The outlook for ZBH is positive, driven by consistent earnings beats and strategic growth initiatives, but investors face risks from margin pressure and increasing debt levels. The stock offers potential upside to the consensus target, supported by institutional accumulation, though competitive and macroeconomic headwinds in the medtech sector warrant caution.
Trailing returns across standard periods
Latest headlines on both assets
FuelCell Energy Inc is a fuel-cell power company. FuelCell designs manufactures, sells, installs, operates, and services fuel cell products, which efficiently convert chemical energy in fuels into electricity through a series of chemical reactions. It serves various industries such as Industrial, Wastewater treatment, Commercial and Hospitality, Data centers and Communications, Education and Healthcare, and others. Geographically, the company generates a majority of its revenue from the United States followed by South Korea.
Read more on FCEL →Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →